CoreCap Advisors LLC Sells 2,663 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CoreCap Advisors LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 90.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 266 shares of the biopharmaceutical company’s stock after selling 2,663 shares during the period. CoreCap Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $189,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Crestline Management LP grew its position in Regeneron Pharmaceuticals by 259.4% in the fourth quarter. Crestline Management LP now owns 2,789 shares of the biopharmaceutical company’s stock worth $1,987,000 after acquiring an additional 2,013 shares in the last quarter. Cutter Capital Management LP boosted its position in Regeneron Pharmaceuticals by 117.6% during the fourth quarter. Cutter Capital Management LP now owns 31,500 shares of the biopharmaceutical company’s stock valued at $22,438,000 after buying an additional 17,024 shares during the period. Capitolis Liquid Global Markets LLC raised its stake in shares of Regeneron Pharmaceuticals by 128.9% during the fourth quarter. Capitolis Liquid Global Markets LLC now owns 87,000 shares of the biopharmaceutical company’s stock valued at $61,973,000 after acquiring an additional 49,000 shares during the last quarter. Cetera Investment Advisers raised its stake in shares of Regeneron Pharmaceuticals by 5.6% during the fourth quarter. Cetera Investment Advisers now owns 9,239 shares of the biopharmaceutical company’s stock valued at $6,581,000 after acquiring an additional 494 shares during the last quarter. Finally, BOKF NA raised its stake in shares of Regeneron Pharmaceuticals by 83.6% during the fourth quarter. BOKF NA now owns 3,203 shares of the biopharmaceutical company’s stock valued at $2,232,000 after acquiring an additional 1,458 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 3.6%

Shares of REGN stock opened at $527.78 on Monday. The company has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a one year low of $517.48 and a one year high of $1,211.20. The company’s fifty day moving average price is $613.08 and its 200-day moving average price is $693.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $9.55 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on REGN. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Bank of America decreased their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. Finally, Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating on the stock in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $892.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.